about
Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitorsGenetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapyMedical treatment of early stage and rare histological variants of epithelial ovarian cancerClinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancerClinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C statusPathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancerGene expression profiling reveals activation of the FA/BRCA pathway in advanced squamous cervical cancer with intrinsic resistance and therapy failureHereditary ovarian cancer: not only BRCA 1 and 2 genes.SATB1 expression is associated with biologic behavior in colorectal carcinoma in vitro and in vivo.HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy.Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraftPost-mortem testing; germline BRCA1/2 variant detection using archival FFPE non-tumor tissue. A new paradigm in genetic counseling.'BRCAness' and its implications for platinum action in gynecologic cancer.Ovarian cancer treatment: The end of empiricism?Ovarian cancer: in search of better marker systems based on DNA repair defectsEvaluating cell lines as tumour models by comparison of genomic profiles.Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib.Ovarian cancer: genomic analysis.The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe.The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future.Embracing synthetic lethality of novel anticancer therapies.A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunityOvarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma.Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer.Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer.Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer.Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)
P2860
Q26768267-9F18E3BA-0977-4141-9FE9-911C2A7B1BB6Q26769604-6C5679C5-AD86-4078-81BF-FCAA10C59D42Q26777702-A2691CE6-90FD-4B5B-B068-8CDD9A15E462Q27024235-9B39E616-3C00-4326-9715-99268CD29397Q28307436-4E0819A1-E210-4DCC-8A21-DE98B240E04FQ28538059-E2F8C5D1-E4F1-4F7F-BD60-624593E75FEAQ30578079-24A83F63-434A-46A6-87E6-EC7BF1977100Q34480707-6DF1AD12-90A9-4D0F-BE37-A9C4C33629E6Q34550828-52D61758-2562-4EF3-9886-4C474F5DF2A7Q35175294-1EA45382-8694-4738-9678-84C5568E488EQ35592388-B4B119D1-374A-4223-9CF8-635FAA02773CQ35886203-A3BC6C3D-1DD1-4FFA-81CF-9CB863B1D664Q36380704-24D00255-0792-48E4-91D9-BC4B89A60702Q36554444-94E42F00-D54C-4998-96D5-0B988862AC8AQ36589947-9CD2EE53-9D78-43B6-8F40-C185B874C55BQ37025950-F72279B5-4E94-4AAD-975A-FBA227793A71Q37169959-8D8672D6-E993-4C4B-B32C-179D70EA6C94Q37332480-95BA957D-D2B9-44B2-8602-D3D3D7100FF8Q37385372-B324F069-3E0C-4874-979E-6DEE04DFEF66Q38282823-D8CB3CF7-405A-43EE-8746-6AEE3A5AE03AQ38554530-AC55F35F-F6D6-47D0-995B-5C6DFA364B42Q38584379-47EA016D-452B-4550-8327-741A0AA40D52Q38796030-85AA0E9A-D36C-422E-94F8-23669C394911Q39245474-25F462C9-AA27-4F88-9B4C-CE7A06E6024DQ40035188-3A0A4D28-3FB4-49AA-AD68-BBE187FF19ECQ40078610-B8F8B874-C39F-4B3F-AA8A-52CB0EFE461AQ47145727-4BABC94A-31B8-45AB-8C07-D29EC99208A8Q48110433-53CA11D4-C61D-4192-8497-DB2175DB88CFQ49826020-0B16619D-9A72-4F68-B93A-3D29D6229478Q52715788-B2E7E830-0B30-47B9-9EA7-01ADDCC0B50FQ58803839-51F5F5D4-1780-4EAA-82F9-45159F0579AB
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
BRCAness: finding the Achilles heel in ovarian cancer
@ast
BRCAness: finding the Achilles heel in ovarian cancer
@en
BRCAness: finding the Achilles heel in ovarian cancer
@nl
type
label
BRCAness: finding the Achilles heel in ovarian cancer
@ast
BRCAness: finding the Achilles heel in ovarian cancer
@en
BRCAness: finding the Achilles heel in ovarian cancer
@nl
prefLabel
BRCAness: finding the Achilles heel in ovarian cancer
@ast
BRCAness: finding the Achilles heel in ovarian cancer
@en
BRCAness: finding the Achilles heel in ovarian cancer
@nl
P2860
P1433
P1476
BRCAness: finding the Achilles heel in ovarian cancer
@en
P2093
Evangelia Razis
Georgios Rigakos
P2860
P304
P356
10.1634/THEONCOLOGIST.2012-0028
P407
P577
2012-01-01T00:00:00Z